Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of the study drug 2141-V11 in people whose
NMIBC did not respond to standard treatment, and who will not have the standard surgical
procedure to remove the bladder. The researchers will test different doses of 2141-V11 to see
which dose is safest in people. The researchers will also do tests to see how the body
absorbs, distributes, and gets rid of 2141-V11. This study is one of the first to test
2141-V11 in people, and the first to test 2141-V11 delivered through a catheter into the
bladder.
Phase:
Phase 1
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Pin Down Bladder Cancer Research Foundation Rockefeller University